A headline about a blood test or a new Alzheimer’s medicine can bring hope, followed by difficult questions. Could this help Mum? Should Dad have another assessment? Does it change the support we have already arranged?
Alzheimer’s research matters, but families should not have to interpret every announcement alone. The useful questions are what a development has actually shown, whether it applies to the person and what remains uncertain.
This guide is for families in England supporting someone with Alzheimer’s disease or undergoing assessment. It explains selected developments without treating a research headline as individual medical advice.
Research and treatment information checked: 29 October 2026. Availability and recommendations can change; ask the memory service or specialist team about the current position.
Why Alzheimer’s Research Can Feel Closer Than Ever
Research is producing new ways to investigate the biological changes associated with Alzheimer’s, alongside treatments intended to slow its progression. However, better testing, slowing decline and reversing a disease are different achievements.
There is currently no cure for Alzheimer’s disease. Treatments and other support can nevertheless help with symptoms and everyday life. The NHS treatment guide explains the established options.
For a family, the most useful question is:
“Does this development change what we should discuss or arrange for this person, at this stage?”
Sometimes it may justify a specialist conversation. At other times, the immediate priority remains improving the assistance already available at home.
What Current Research May Change
Earlier and More Accurate Diagnosis
Blood tests are attracting attention because researchers are investigating whether they can identify markers associated with Alzheimer’s more accessibly than some existing specialist investigations.
One example is p-tau217, a form of the tau protein measured in blood. The UK’s ADAPT study is examining its use in memory services, including whether earlier access to results improves diagnosis and subsequent decisions. READ-OUT is evaluating several blood tests and how they perform across different people and clinical settings. These studies form part of the Blood Biomarker Challenge.
Research within NHS services is not the same as a test being routinely available to everyone through the NHS. The programme is gathering evidence about accuracy, practical implementation and the effect on patients and care. Its aims should not be presented as a guaranteed date for nationwide availability.
There is another distinction worth understanding. The blood tests a GP already requests when investigating memory concerns may check thyroid function, vitamin levels or other possible causes. They are not necessarily Alzheimer’s biomarker tests.
A diagnosis draws on the person’s symptoms, history, daily functioning and appropriate investigations. A laboratory result does not replace that wider assessment. The NHS guide to dementia tests explains the process.
Before arranging a test privately, ask what question it would answer, who would interpret it and how the result would change care. Discuss what an uncertain result would mean as well as a positive or negative one.
Medicines That Aim to Slow Progression
Two medicines frequently mentioned in research coverage are lecanemab and donanemab. They target amyloid, a protein that accumulates in the brains of people with Alzheimer’s disease.
Their UK licences cover selected adults with mild cognitive impairment or mild dementia due to Alzheimer’s—not every person with dementia. Treatment requires evidence of amyloid changes and specialist assessment. The licences also restrict use according to the person’s APOE ε4 genetic status, because this affects the balance of benefit and risk.
The distinction between slowing decline and improvement is important. In the pivotal lecanemab trial, the treated group declined less on average than the placebo group over 18 months. That is not the same as participants regaining lost memory or the disease being stopped.
These treatments also involve more than receiving a prescription. Specialist services must consider suitability, other medicines, brain imaging and ongoing monitoring. Risks include swelling or bleeding in the brain, which can sometimes be serious. MRI monitoring forms part of treatment.
A family should therefore ask about the likely benefit and the risks, appointments, travel and monitoring involved. Do not change an existing prescription or care arrangement in response to a headline.
A UK Licence Is Not the Same as NHS Funding
Licensing and routine NHS access are separate decisions. A medicine being authorised for a particular group does not mean that every eligible person can receive it through the NHS.
At the time of this check, NICE’s appraisals for both medicines remain in development. Its published timelines record pauses for commercial discussions between the manufacturers and NHS England: 29 July 2026 for lecanemab and 30 July 2026 for donanemab. The final publication dates remain unconfirmed.
The current position can be checked on NICE’s lecanemab appraisal page and NICE’s donanemab appraisal page.
Do not interpret those discussions as an announcement of final NHS approval. Ask the specialist team what access routes, if any, are available for the individual and whether treatment would be clinically appropriate.
Existing Treatments Still Matter
Coverage of newer medicines should not suggest that established treatment has become irrelevant.
Medicines such as donepezil, galantamine, rivastigmine and memantine remain options for managing Alzheimer’s symptoms in appropriate circumstances. They have different roles from medicines targeting amyloid, and suitability should be discussed with the treating clinician.
For someone already receiving treatment, a useful question is whether their current plan needs reviewing—not whether the latest announcement means everything should be replaced.
Research Into Living Well With Dementia
Not all useful evidence concerns medicines or diagnostic tests.
NICE recommends activities tailored to the person’s preferences and group cognitive stimulation therapy for people with mild to moderate dementia. It also advises considering cognitive rehabilitation or occupational therapy to support everyday functioning.
These approaches have different purposes. Cognitive stimulation involves structured activities and discussion. Cognitive rehabilitation focuses on personally meaningful practical goals, such as managing an everyday task with appropriate strategies and assistance. Neither should be described as a cure.
Ask what support is available locally and whether it suits the person. A group session may appeal to one individual, while another needs a different approach to participation.
Research about reducing someone’s future risk of dementia also needs separating from evidence about treating established Alzheimer’s disease. A promising finding in people without symptoms does not automatically show that the same approach will reverse difficulties in someone already diagnosed.
Three Checks Before a Headline Changes Your Plans
1. Who Took Part?
Was the research conducted in a laboratory, in animals or with people? If people took part, what stage of the condition did they have?
Ask whether the participants’ circumstances resemble those of your relative. Research in carefully selected people with early Alzheimer’s cannot simply be applied to every dementia diagnosis or stage.
For example, the major lecanemab trial studied people with early Alzheimer’s disease. Its results should be understood within that population and the trial’s eligibility requirements.
2. What Actually Improved?
Look for the outcome measured. Was it a biological marker, a memory-and-thinking score, daily functioning or the experience of the person and their family?
A percentage reduction in decline is not a percentage improvement in memory. It also does not tell you, by itself, how many extra years of independence a particular person will experience.
Ask the clinician to explain both the size of the difference and what it might mean in ordinary life. An average trial result cannot promise the same outcome for every participant.
3. What Would Taking Part or Receiving Treatment Involve?
Consider appointments, tests, travel, side effects and the person’s wishes alongside any potential benefit.
Ask whether the report describes an early research finding, a completed trial, a licensed treatment or a service available in the relevant NHS setting.
A decision not to pursue an unsuitable or burdensome option is not a failure to seek good care. The aim is an informed choice, not a response driven by fear of missing an opportunity.
Taking Part in Research Is a Separate Decision
Some families want to contribute to research rather than only follow the news.
Join Dementia Research connects volunteers with studies. Opportunities can involve people with dementia, relatives and people without a diagnosis, depending on each study’s requirements. Research is not limited to medicine trials.
Registration does not guarantee eligibility, a place in a study or access to treatment. It also does not commit someone to participating. The research team should explain the particular study so the person can ask questions and decide whether to proceed.
Ask about the purpose, possible burdens, what results will be shared and how the person’s wishes and consent will be respected.
The Part Research Cannot Replace
While tests and treatments develop, the person still has a day to live.
Ask what they want help with now. They may want to choose their clothes, participate in preparing lunch or enjoy a familiar activity without being hurried. Consider the assistance that makes those choices possible rather than treating care as a fixed list of tasks.
Practical questions remain important: is medication support clearly agreed? Are meals manageable? Does the person have the assistance they need to move around? Is technology at home genuinely helpful, or adding confusing prompts?
Live In Care Ltd is a family-owned, CQC-regulated provider of fully managed live-in care across England. Our role is to assess and provide appropriate practical support—not to diagnose Alzheimer’s or decide eligibility for specialist treatment.
Where one-to-one dementia support at home is being considered, discuss the person’s current needs, preferences and clinical guidance. Breaks, rest and any additional night support must also be planned; a live-in arrangement is not one person providing continuous active care throughout every day and night.
Research news is a reason to ask informed questions, not to postpone assistance that is already needed.
Questions Worth Taking to a Clinical Appointment
Bring the article or study that prompted your questions so the clinician knows exactly what you have read.
You could ask:
- Does this development apply to the diagnosis and stage we are dealing with?
- Would another test change treatment or care, and what are its limitations?
- What benefit, risks and practical commitments would a proposed treatment involve?
- What support or treatment should we review now, regardless of future developments?
Explain changes at home as well as concerns about memory: meals, medicines, personal care, sleep and the responsibilities relatives are carrying.
There is no need to arrive with a conclusion. A useful appointment should help distinguish a relevant option from something still being investigated or unsuitable for that person.
Keeping Hope Practical
Hope does not need to depend entirely on the next announcement. It can also mean getting a clearer explanation, reviewing treatment, arranging manageable assistance or protecting time for relationships.
When you contact our care team, explain what has become difficult and what the person wants to preserve about life at home. A care assessment can explore practical support alongside advice from the healthcare professionals already involved.
Keep following research with curiosity, but return to the same question: what would help this person, now, while preserving their voice and choices?
That allows scientific progress and thoughtful everyday care to have their proper place—without asking either to promise more than it can deliver.